STTK

Shattuck Labs Inc

5.76

Oct 21 • 4:44 AM ET -0.08 (-1.37%)

Healthcare Biotechnology USA Small NASD

Peers: SYRE ROIV AGMB ODTX MLTX ABVX MRK PTGX TEVA SNY

| Held by: VTI IWM XBI VXF IWO VTWO FESM VFMO VHT IWC

Index	RUT
Market Cap	578.09M
Enterprise Value	372.46M
Income	-52.57M
Sales	1.00M
Book/sh	2.10
Cash/sh	2.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	Oct 09, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	578.09
P/B	2.75
P/C	2.78
P/FCF	-
EV/EBITDA	-
EV/Sales	372.46
Quick Ratio	27.59
Current Ratio	27.59
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.51
EPS next Y	-0.52
EPS next Q	-0.11
EPS this Y	30.68%
EPS next Y	-6.83%
EPS next 5Y	5.95%
EPS past 3/5Y	33.69% 4.36%
Sales past 3/5Y	15.32% -36.82%
EPS Y/Y TTM	57.89%
Sales Y/Y TTM	-66.63%
EPS Q/Q	52.19%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	3.30% -

Insider Own	14.10%
Insider Trans	-0.17%
Inst Own	71.88%
Inst Trans	32.41%
ROA	-36.88%
ROE	-39.21%
ROIC	-24.69%
Gross Margin	-256.50%
Oper. Margin	-5570.60%
Profit Margin	-5256.80%
SMA20	-4.17%
SMA50	-11.89%
SMA200	-3.98%
Trades

Shs Outstand	100.73M
Shs Float	86.22M
Short Float	12.70%
Short Ratio	9.59
Short Interest	10.95M
52W High	8.33 -30.85%
52W Low	1.72 234.88%
Volatility	6.72% 8.00%
ATR (14)	0.43
RSI (14)	45.04
Beta	1.19
Rel Volume	0.00
Avg Volume	1.14M
Volume	9

Perf Week	8.07%
Perf Month	-11.38%
Perf Quarter	-18.76%
Perf Half Y	-25.68%
Perf YTD	57.81%
Perf Year	200.00%
Perf 3Y	311.43%
Perf 5Y	-70.12%
Perf 10Y	-
Recom	1.00
Target Price	16.00
Prev Close	5.84
Price	5.76
Change %	-1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Initiated	UBS	Buy	$17
Aug-24-26	Initiated	Raymond James	Strong Buy	$18
Jul-20-26	Initiated	Leerink Partners	Outperform	$16
Apr-27-26	Initiated	Cantor Fitzgerald	Overweight
Mar-06-26	Resumed	Needham	Buy	$25
Jan-28-26	Initiated	Piper Sandler	Overweight	$15
Dec-01-25	Upgrade	H.C. Wainwright	Neutral → Buy	$6
Sep-08-25	Initiated	Wedbush	Outperform	$4
Mar-17-25	Initiated	Leerink Partners	Outperform	$4
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-02-24	Downgrade	Citigroup	Buy → Neutral	$8 → $2
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy	$12
Jun-01-22	Initiated	Citigroup	Buy	$13
May-02-22	Initiated	H.C. Wainwright	Buy	$28
Apr-14-21	Initiated	Berenberg	Buy	$47
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Needham	Buy	$34
Nov-03-20	Initiated	Cowen	Outperform

Show Previous Ratings

Oct-13-26 08:00AM	Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 (GlobeNewswire) -9.85%
Oct-01-26 07:00AM	Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development (GlobeNewswire)
Sep-02-26 04:05PM	Shattuck Labs Announces Participation in Upcoming September Investor Conferences (GlobeNewswire)
Aug-11-26 06:15AM	Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-24-26 09:32AM	SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls (The Fly)
09:39AM	Loading…
Jul-20-26 09:39AM	Netflix upgraded, Microsoft initiated: Wall Street's top analyst calls (The Fly) -9.43%
Jun-10-26 12:21AM	Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering (GlobeNewswire)
Jun-09-26 04:18PM	Shattuck Labs, Inc. Announces Proposed Public Offering (GlobeNewswire) +9.49%
08:00AM	Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update (GlobeNewswire)
Jun-08-26 06:00AM	Shattuck Labs Announces Phase 1 Results for SL-325 (GlobeNewswire) -14.85%
Jun-05-26 04:05PM	Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 (GlobeNewswire)
May-07-26 06:15AM	Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -6.29%
Mar-05-26 06:15AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +7.82%
Feb-25-26 08:00AM	Shattuck Labs Announces Participation in Upcoming March Investor Conferences (GlobeNewswire) -5.37%
Feb-06-26 08:30AM	Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire) +5.60%
10:50PM	Loading…
Jan-05-26 10:50PM	Why Shattuck Labs Stock Soared in December (Motley Fool)
Dec-15-25 04:15PM	Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-25 01:26AM	Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result (Insider Monkey)
Nov-20-25 08:00AM	Shattuck Labs to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-06-25 04:30PM	Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-08-25 12:00PM	What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-02-25 07:51AM	Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel (GlobeNewswire)
Sep-19-25 09:55AM	Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross? (Zacks)
Sep-08-25 05:09PM	Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +21.29% +6.91%
Aug-26-25 06:30AM	Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors (GlobeNewswire)
Aug-21-25 10:17AM	Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease (GlobeNewswire) -11.42%
Aug-14-25 06:30AM	Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +33.30%
06:30AM	Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million (GlobeNewswire)
Jul-02-25 07:00AM	Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
04:20PM	Loading…
May-01-25 04:20PM	Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +9.20% -7.81%
Apr-02-25 05:00PM	Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.28% -17.34%
Mar-27-25 07:00AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-20-25 09:00AM	Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire)
Feb-13-25 04:30PM	Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire) +5.04% +6.40%
Feb-04-25 07:00AM	Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress (GlobeNewswire)
Jan-06-25 04:59PM	Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.22%
Jan-03-25 07:15AM	Shattuck Labs highlights upcoming key milestones in 2025 (TipRanks) +10.74%
Jan-02-25 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 (GlobeNewswire)
Nov-25-24 07:00AM	Shattuck Labs Announces Participation in Upcoming December Conferences (GlobeNewswire)
Nov-15-24 07:12AM	Shattuck Labs sees cash runway into 2027 (TipRanks) -9.85%
Nov-14-24 07:00AM	Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +12.30%
Oct-24-24 09:35AM	Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround (Zacks)
Oct-08-24 09:35AM	After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks) +11.50%
Oct-02-24 11:32AM	Shattuck Labs stock craters following pipeline and job cuts (Pharmaceutical Technology) -34.90%
06:57AM	Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts (TipRanks)
Oct-01-24 12:26PM	Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline (Benzinga) -44.99%
06:30AM	Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway (GlobeNewswire)
Aug-01-24 06:20PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.28%
04:05PM	Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-30-24 05:00PM	Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-01-24 06:00AM	Shattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-18-24 06:25PM	Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK) (Insider Monkey) -7.83% -9.26%
10:48AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Jun-14-24 01:28PM	Shattuck (STTK) Announces Positive Interim Data on Cancer Drug (Zacks) -9.50%
06:00AM	Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Jun-10-24 07:30AM	Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jun-06-24 07:30AM	Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
May-21-24 09:35AM	After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks)
May-14-24 04:15PM	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire) -18.07%
May-07-24 12:00PM	What Makes Shattuck Labs (STTK) a New Buy Stock (Zacks)
09:55AM	Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect? (Zacks)
May-04-24 05:31AM	Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-02-24 09:58PM	STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:25AM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-09-24 04:05PM	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +8.44%
Apr-01-24 07:00AM	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Feb-29-24 04:05PM	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +10.54%
Feb-26-24 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-14-24 05:06AM	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins (PR Newswire) +6.03%
Feb-13-24 06:00AM	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.37%
Jan-08-24 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 (GlobeNewswire) +14.94%
Jan-04-24 04:05PM	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.14%
Dec-21-23 08:00AM	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire)
Dec-13-23 10:45AM	Why Is Shattuck Labs (STTK) Stock Up 93% Today? (InvestorPlace) +130.33%
06:00AM	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Dec-05-23 04:15PM	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023 (GlobeNewswire) +22.56%
Nov-14-23 09:00AM	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +10.05%
Nov-13-23 08:52AM	Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 11:54PM	Q3 2023 Shattuck Labs Inc Earnings Call (Thomson Reuters StreetEvents) -23.21%
08:29AM	Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
06:00AM	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-06-23 09:28AM	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire) +14.05%
Nov-02-23 09:01AM	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +7.69%
Aug-10-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.64%
04:00PM	Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-23 10:14AM	Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky (Simply Wall St.) -7.07%
May-25-23 05:15PM	Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) -5.46%
May-09-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.56%
04:00PM	Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-03-23 07:00AM	Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-23 11:50AM	Great week for Shattuck Labs, Inc. (NASDAQ:STTK) institutional investors after losing 37% over the previous year (Simply Wall St.)
Mar-16-23 08:31AM	Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +8.93%
Mar-01-23 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-27-23 10:46PM	Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 04:30PM	Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-16-23 07:00AM	Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shukla Abhinav A.	Chief Technical Officer	Jul 06 '26	Option Exercise	3.57	12,153	43,386	98,533	Jul 07 07:00 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 02 '26	Option Exercise	3.57	410	1,464	86,790	Jul 07 07:00 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 02 '26	Sale	7.01	410	2,874	86,380	Jul 07 07:00 PM
Shukla Abhinav A.	Chief Technical Officer	Jun 30 '26	Option Exercise	3.57	23,365	83,413	109,745	Jul 02 08:17 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 01 '26	Option Exercise	3.57	100	357	86,480	Jul 02 08:17 PM
Shukla Abhinav A.	Chief Technical Officer	Jun 30 '26	Sale	7.08	23,365	165,424	86,380	Jul 02 08:17 PM
Shukla Abhinav A.	Chief Technical Officer	Jul 01 '26	Sale	7.07	100	707	86,380	Jul 02 08:17 PM
Pandite Arundathy N.	Chief Medical Officer	Jun 30 '26	Sale	7.01	30,000	210,300	136,219	Jul 02 08:15 PM
Shukla Abhinav A.	Officer	Jul 02 '26	Proposed Sale	7.01	410	2,874		Jul 02 04:24 PM
Shukla Abhinav A.	Officer	Jul 01 '26	Proposed Sale	7.07	100	707		Jul 01 04:19 PM
Shukla Abhinav A.	Officer	Jun 30 '26	Proposed Sale	7.08	23,365	165,469		Jun 30 04:10 PM
SIEGALL CLAY B	Director	Jun 09 '26	Buy	4.00	62,500	250,000	318,608	Jun 11 05:00 PM
Shukla Abhinav A.	Chief Technical Officer	May 12 '26	Option Exercise	3.57	2,032	7,254	83,290	May 14 08:05 PM
Shukla Abhinav A.	Chief Technical Officer	May 12 '26	Sale	7.01	2,032	14,244	81,258	May 14 08:05 PM
Pandite Arundathy N.	Chief Medical Officer	May 12 '26	Sale	6.61	30,000	198,300	166,219	May 14 08:00 PM
ARUNTHATHY PANDITE	Officer	May 12 '26	Proposed Sale	7.02	60,000	421,200		May 12 04:33 PM
Shukla Abhinav A.	Officer	May 12 '26	Proposed Sale	7.01	2,032	14,236		May 12 04:17 PM

Shattuck Labs, Inc. is a clinical-stage biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Ph.D.Dr. Taylor H. Schreiber M.D.

Chief Financial OfficerMr. Andrew R. Neill M.B.A.

M.D.Dr. Arunthathy Nirmalini Pandite M.B.A.

Vice President of Accounting & SEC reportingMr. Brad Huckabee

Chief Technical OfficerDr. Abhinav A. Shukla Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STTK

Shattuck Labs Inc

Upgrade your Finviz experience